Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
ACS Medicinal Chemistry Letters
|
February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Nature Communications
|
January 11, 2019
A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition
Christopher E Mahoney, David Pirman, Victor Chubukov, et al.
Science (New York, N.Y.)
|
April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Cancer Cell
|
January 15, 2021
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
Peter Kalev, Marc L Hyer, Stefan Gross, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities
Pratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Nature
|
June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M Intlekofer, Alan H Shih, Bo Wang, et al.
Science (New York, N.Y.)
|
April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Fang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Blood Advances
|
May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Sung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Journal of Medicinal Chemistry
|
February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Nature
|
April 20, 2018
Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis
Monika Bambouskova, Laurent Gorvel, Vicky Lampropoulou, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
ACS Medicinal Chemistry Letters
|
February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Nature Communications
|
January 11, 2019
A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition
Christopher E Mahoney, David Pirman, Victor Chubukov, et al.
Science (New York, N.Y.)
|
April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Cancer Cell
|
January 15, 2021
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
Peter Kalev, Marc L Hyer, Stefan Gross, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities
Pratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Nature
|
June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M Intlekofer, Alan H Shih, Bo Wang, et al.
Science (New York, N.Y.)
|
April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Fang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Blood Advances
|
May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Sung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Journal of Medicinal Chemistry
|
February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Nature
|
April 20, 2018
Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis
Monika Bambouskova, Laurent Gorvel, Vicky Lampropoulou, et al.
Page
of 8